Home

GREGORY D PERRY

CIK 1236371 · Chief Financial Officer & PFO · last filed 2025-12-12

GREGORY D PERRY is a Chief Financial Officer & PFO who has filed 63 SEC Form 4 insider transactions across 8 companies since 2009. The most recent filing, for MRUS, was dated Dec 12, 2025. Across all open-market trades the lifetime net is −$953.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $153 across reported positions. 4 SEC filings were submitted jointly with QLT INC/BC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$153

Companies

8

Total Filings

63

Lifetime Open-Market Net

-$953.6K

Filer Profile

Reported Address
C/O IMMUNOGEN, INC.
830 WINTER ST.
WALTHAM, MA 02451
Related Filers
QLT INC/BC — 4 joint filings, latest 2017-05-11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Merus N.V. (MRUS) Delisted Chief Financial Officer & PFO — $90.00 — $0 8 2025-12-12
KALA Director 267 $0.57 $153 $0 9 2025-06-17
Finch Therapeutics Group, Inc. (FNCH) Delisted Chief Financial Officer — $7.30 — $0 1 2022-02-28
NOVELION THERAPEUTICS INC. (NVLN) Delisted See Remarks 1,683 — — $0 2 2017-05-11
Aegerion Pharmaceuticals, Inc. (AEGR) Delisted See Remarks — — — $0 5 2016-11-30
Ocata Therapeutics, Inc. (OCAT) Delisted Director 0 — — $0 7 2016-02-11
Carisma Therapeutics Inc. (EBIO) Delisted Chief Financial and Business — — — $0 1 2015-02-27
ImmunoGen, Inc. (IMGN) Delisted Chief Financial Officer 18,337 $31.23 $572.7K -$953.6K 14 2013-09-11

Recent Filings

63 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-12-12 Merus N.V. (MRUS) Delisted Disp (D) — $0 EDGAR
2025-06-17 KALA Grant (A) +2,450 $0 EDGAR
2025-01-31 Merus N.V. (MRUS) Delisted Grant (A) — $0 EDGAR
2024-06-12 KALA Grant (A) +1,400 $0 EDGAR
2024-05-09 Merus N.V. (MRUS) Delisted Grant (A) — $0 EDGAR
2023-06-23 KALA Grant (A) +6,956 $0 EDGAR
2023-06-15 Merus N.V. (MRUS) Delisted Grant (A) — $0 EDGAR
2023-06-12 Merus N.V. (MRUS) Delisted Grant (A) — $0 EDGAR
2023-06-02 KALA Mixed +1,738 $0 EDGAR
2022-06-17 KALA Grant (A) — $0 EDGAR
Showing 1–10 of 63
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.